Alliance pancanadienne pharmaceutique (APP) – dernières mises à jour

État Nombre total Résumé
Négociations actives 38 Non liées à l’oncologie: 26
Liées à l’oncologie: 12
Négociations envisagées 26 Non liées à l’oncologie: 13
Liées à l’oncologie: 13
Négociations terminées 505 Avec lettre d’intention: 438
Sans entente: 67
Négociations qui n’ont pas eu lieu 89

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Tukysa Seagen Canada Inc. Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment wit
Tagrisso AstraZeneca Canada Inc. Indicated as adjuvant therapy after tumour resection in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
Sarclisa Sanofi Genzyme In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy
Sarclisa Sanofi Genzyme Isatuximab in combination with pomalidomide and dexamethasone, for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.
Dojolvi Ultragenyx Canada Inc. long-chain fatty acid oxidation disorders

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Ogivri BGP Pharma ULC Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Kanjinti Amgen Canada Inc. Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Ontruzant Organon Canada Inc. Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)
Inrebic Celgene Inc. Treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been prev
Herzuma Teva Canada Limited Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Trazimera Pfizer Canada ULC Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Kyprolis Amgen Canada Inc. Treatment of multiple myeloma (including relapsed)
Vyxeos Jazz Pharmaceuticals Canada Inc. For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Vascepa HLS Therapeutics Inc. Ischemic events in statin-treated patients

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Phesgo SC HOFFMANN-LA ROCHE LIMITED For the first-line treatment of patients with HER2-positive metastatic breast cancer
Opsynvi Janssen Inc. pulmonary arterial hypertension
Inqovi Taiho Pharma Canada, Inc. Inqovi (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory an

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation
Tavalisse Medison Pharma Canada chronic immune thrombocytopenia
Adtralza LEO Pharma Inc. atopic dermatitis
Myinfla Pendopharm, a division of Pharmascience Inc. atherothrombotic events in coronary artery disease